Henry McCusker's  Instablog

Henry McCusker
Send Message
Analyst, Journalist and Publisher ... Henry enters his tenth (10) year at Scimitar Equity -Regenerative Medicine Investors which aggregates, curates and creates bottom-line content weeding of regenerative medicine and cell therapy news to provide a customized, vetted selection of relevant and... More
My company:
Scimitar Equity-Regenerative Medicine Investors
My blog:
Scimitar Equity Blog
  • STEMGENT Raises $5.6 M and Partnership with Miltenyi Biotec 0 comments
    May 18, 2010 8:33 AM

    Stemgent, a Cambridge-based stem cell technology company, raised $5.6 M of a $10 M round in venture capital, according to a new filing with the SEC. The funding also includes the conversion of promissory notes. Stemgent’s previous investors, Morganthaler Partners  and HealthCare Ventures were both included in the filing (5/12/10) with the SEC. The filing also included Stefan Miltenyi, CEO of Miltenyi Biotec, who will also make an equity investment into Stemgent and join Stemgent’s Board of Directors. 

    Miltenyi Biotec is a German cellular therapeutics firm entered into a co-development and commercialization agreement for stem cell research products with Stemgent: Miltenyi Biotec will be responsible for worldwide marketing and sales of Stemgent’s existing stem cell product portfolio outside the USA, whereas Stemgent will continue to serve its US customers. Both companies will jointly develop innovative products to serve unmet needs of the international stem cell research community. New products developed in the strategic collaboration will be globally commercialized by Miltenyi Biotec on an exclusive basis.

    A year earlier, in 3/09, Stemgent raised a $14 M Series A-1 round of funding. In 3/10, Stemgent announced that it had invested $4.5 M to co-found Ubiquigent, a Scottish company developing cell signaling products that Stemgent will market in the US.  Ian Radcliffe plans to serve as CEO of Uniquigent, as well as Stemgent.

    Miltenyi Biotec provides products and services for cellular therapies. With approx. 1100 employees in 18 countries, Miltenyi Biotec develops manufactures and commercializes innovations for both, research and clinical applications. The port­folio provides integrated solutions for all areas covering sample preparation, cell separation, cell culture, flow cytometry, and molecular analysis.

    Our previous blog on 4/19/10 defined:  Stemgent, as a start-up in Cambridge, MA and San Diego, Cal that makes consumable materials for stem cell research labs. Stemgent provides research tools and services to advance in vitro and in vivo nonhuman stem cell research. Its product offering includes small molecules for pluripotency, self-renewal, and differentiation, viral-delivered transcription factors, matrices, cell lines, cytokines, antibodies, transfection reagents, and more. It has obtained licenses related to stem cell reagents from research institutions such as MIT, Harvard University and The Scripps Research Institute in La Jolla, Cal.

Back To Henry McCusker's Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Comments (0)
Track new comments
Be the first to comment
Full index of posts »
Latest Followers

StockTalks

  • ImmunoCellular (OTC BB: IMUC) files to Sell $13.8M of Units via Cowen
    Nov 30, 2011
  • Mid-Day Movers: BioTime (AMEX: BTX), Cytori (CYTX), Geron (GERN), Neuralstem (AMEX: CUR), ReNeuron (RENE.LON), ThermoGenesis (KOOL)
    Oct 26, 2011
More »

Latest Comments


Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.